Solid Tumor Testing Market Size, Share, Trends, Growth Outlook

Solid Tumor Testing Market is estimated to increase at a growth rate of 7.4% CAGR over the forecast period from 2024 to 2030.

The global Solid Tumor Testing Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Genetic Testing, Conventional Testing), By Application (Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, Brain, Thyroid, Liver, Ovarian, Others), By End-user (Pharmaceutical and Biotechnology Companies, Hospitals, Contract Research Organizations, Academic Research Institutions).

An introduction to Solid Tumor Testing Market in 2024

Empowering precision oncology and personalized cancer treatment, the Solid Tumor Testing Market offers comprehensive genomic profiling and molecular diagnostic tests designed to identify genetic alterations, biomarkers, and therapeutic targets in solid tumors for guiding treatment decisions and optimizing patient outcomes. Solid tumor testing encompasses a variety of techniques, including next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC), performed on tumor tissue samples or liquid biopsies. This market serves oncologists, pathologists, and cancer care teams seeking to characterize tumors, predict treatment responses, and select targeted therapies based on individual tumor molecular profiles. Providers include diagnostic laboratories, molecular diagnostics companies, and academic medical centers, offering advanced testing services and comprehensive genomic panels for various cancer types. With the increasing complexity of cancer biology, the advent of targeted therapies, and the emergence of immunotherapy approaches, the demand for solid tumor testing continues to grow, driven by efforts to improve treatment outcomes and reduce treatment-related toxicities in cancer patients. As oncology practices embrace precision medicine and molecularly guided treatment strategies, solid tumor testing plays a pivotal role in advancing personalized cancer care and shaping the future of oncology practice.

Solid Tumor Testing Market Trend: Shift towards Precision Oncology and Personalized Medicine

A prominent trend in the Solid Tumor Testing market is the shift towards precision oncology and personalized medicine approaches for cancer diagnosis and treatment. With advancements in genomic sequencing technologies and molecular profiling techniques, there's a growing understanding of the genetic alterations and molecular signatures underlying solid tumors. This trend has led to the development of targeted therapies and immunotherapies that are tailored to individual patients' tumor profiles, offering the potential for more effective and personalized treatment strategies. As a result, there's increasing demand for comprehensive solid tumor testing solutions that provide accurate molecular characterization of tumors to guide treatment decisions and improve patient outcomes.

Solid Tumor Testing Market Driver: Rising Incidence of Solid Tumors and Cancer Burden

A key driver propelling the growth of the Solid Tumor Testing market is the rising incidence of solid tumors and the increasing cancer burden globally. Solid tumors, including those of the lung, breast, colon, and prostate, are among the most common cancers worldwide, contributing to significant morbidity and mortality. As cancer incidence continues to rise due to factors such as aging populations, lifestyle changes, and environmental exposures, there's a growing need for accurate and timely diagnosis, prognosis, and treatment selection. Solid tumor testing plays a crucial role in oncology care by enabling the detection of genetic mutations, biomarkers, and molecular alterations that inform treatment decisions and guide personalized therapy approaches, driving market demand for comprehensive testing solutions.

Solid Tumor Testing Market Opportunity: Expansion into Liquid Biopsy and Minimal Residual Disease Monitoring

An opportunity in the Solid Tumor Testing market lies in the expansion into liquid biopsy and minimal residual disease (MRD) monitoring technologies for early cancer detection and treatment monitoring. Liquid biopsy techniques, which analyze circulating tumor DNA (ctDNA), RNA, and proteins in blood samples, offer non-invasive methods for detecting tumor-specific mutations and monitoring treatment response over time. Similarly, MRD monitoring involves detecting residual cancer cells in patients who have undergone treatment, allowing for early detection of disease recurrence and adjustment of therapy accordingly. By investing in research and development efforts focused on liquid biopsy technologies and MRD detection assays, companies can expand their offerings to include complementary testing solutions that enhance cancer detection sensitivity, improve patient management, and address unmet needs in cancer care. Additionally, partnering with pharmaceutical companies and healthcare providers to integrate liquid biopsy and MRD monitoring into clinical practice can create opportunities for market growth and adoption of innovative testing approaches in oncology.

Solid Tumor Testing Market Market Segmentation

By Type
Genetic Testing
-Next generation sequencing
-Real-time PCR
-Fluorescent In-Situ Hybridization
-Fragment Analysis
Conventional Testing
By Application
Prostate
Breast
Colorectal
Endometrial
Lung
Melanoma
Brain
Thyroid
Liver
Ovarian
Others
By End-User
Pharmaceutical and Biotechnology Companies
Hospitals
Contract Research Organizations
Academic Research Institutions

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Solid Tumor Testing Market Companies

Abbott Laboratories
Agilent Technologies Inc
AMSBIO
Biocare Medical LLC
BioLifeSolutions Inc
CellGenix GmbH.
Corning Inc
F. Hoffmann-La Roche AG
Illumina Inc
LGC SeraCare
MedGenome Labs Private Ltd
Myriad Genetics Inc
Princeton CryoTech
QIAGEN
Quest Diagnostics Inc
STEMCELL Technologies Inc
Thermo Fisher Scientific Inc

Reasons to Buy the Solid Tumor Testing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Solid Tumor Testing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Solid Tumor Testing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Solid Tumor Testing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Solid Tumor Testing Market Size Outlook, $ Million, 2021 to 2030
3.2 Solid Tumor Testing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Solid Tumor Testing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Solid Tumor Testing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Solid Tumor Testing Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Solid Tumor Testing Industry
4.2 Key Market Trends in Solid Tumor Testing Industry
4.3 Potential Opportunities in Solid Tumor Testing Industry
4.4 Key Challenges in Solid Tumor Testing Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Solid Tumor Testing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Solid Tumor Testing Market Outlook by Segments
7.1 Solid Tumor Testing Market Outlook by Segments, $ Million, 2021- 2030
By Type
Genetic Testing
-Next generation sequencing
-Real-time PCR
-Fluorescent In-Situ Hybridization
-Fragment Analysis
Conventional Testing
By Application
Prostate
Breast
Colorectal
Endometrial
Lung
Melanoma
Brain
Thyroid
Liver
Ovarian
Others
By End-User
Pharmaceutical and Biotechnology Companies
Hospitals
Contract Research Organizations
Academic Research Institutions

8 North America Solid Tumor Testing Market Analysis and Outlook To 2030
8.1 Introduction to North America Solid Tumor Testing Markets in 2024
8.2 North America Solid Tumor Testing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Solid Tumor Testing Market size Outlook by Segments, 2021-2030
By Type
Genetic Testing
-Next generation sequencing
-Real-time PCR
-Fluorescent In-Situ Hybridization
-Fragment Analysis
Conventional Testing
By Application
Prostate
Breast
Colorectal
Endometrial
Lung
Melanoma
Brain
Thyroid
Liver
Ovarian
Others
By End-User
Pharmaceutical and Biotechnology Companies
Hospitals
Contract Research Organizations
Academic Research Institutions

9 Europe Solid Tumor Testing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Solid Tumor Testing Markets in 2024
9.2 Europe Solid Tumor Testing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Solid Tumor Testing Market Size Outlook by Segments, 2021-2030
By Type
Genetic Testing
-Next generation sequencing
-Real-time PCR
-Fluorescent In-Situ Hybridization
-Fragment Analysis
Conventional Testing
By Application
Prostate
Breast
Colorectal
Endometrial
Lung
Melanoma
Brain
Thyroid
Liver
Ovarian
Others
By End-User
Pharmaceutical and Biotechnology Companies
Hospitals
Contract Research Organizations
Academic Research Institutions

10 Asia Pacific Solid Tumor Testing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Solid Tumor Testing Markets in 2024
10.2 Asia Pacific Solid Tumor Testing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Solid Tumor Testing Market size Outlook by Segments, 2021-2030
By Type
Genetic Testing
-Next generation sequencing
-Real-time PCR
-Fluorescent In-Situ Hybridization
-Fragment Analysis
Conventional Testing
By Application
Prostate
Breast
Colorectal
Endometrial
Lung
Melanoma
Brain
Thyroid
Liver
Ovarian
Others
By End-User
Pharmaceutical and Biotechnology Companies
Hospitals
Contract Research Organizations
Academic Research Institutions

11 South America Solid Tumor Testing Market Analysis and Outlook To 2030
11.1 Introduction to South America Solid Tumor Testing Markets in 2024
11.2 South America Solid Tumor Testing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Solid Tumor Testing Market size Outlook by Segments, 2021-2030
By Type
Genetic Testing
-Next generation sequencing
-Real-time PCR
-Fluorescent In-Situ Hybridization
-Fragment Analysis
Conventional Testing
By Application
Prostate
Breast
Colorectal
Endometrial
Lung
Melanoma
Brain
Thyroid
Liver
Ovarian
Others
By End-User
Pharmaceutical and Biotechnology Companies
Hospitals
Contract Research Organizations
Academic Research Institutions

12 Middle East and Africa Solid Tumor Testing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Solid Tumor Testing Markets in 2024
12.2 Middle East and Africa Solid Tumor Testing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Solid Tumor Testing Market size Outlook by Segments, 2021-2030
By Type
Genetic Testing
-Next generation sequencing
-Real-time PCR
-Fluorescent In-Situ Hybridization
-Fragment Analysis
Conventional Testing
By Application
Prostate
Breast
Colorectal
Endometrial
Lung
Melanoma
Brain
Thyroid
Liver
Ovarian
Others
By End-User
Pharmaceutical and Biotechnology Companies
Hospitals
Contract Research Organizations
Academic Research Institutions

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Agilent Technologies Inc
AMSBIO
Biocare Medical LLC
BioLifeSolutions Inc
CellGenix GmbH.
Corning Inc
F. Hoffmann-La Roche AG
Illumina Inc
LGC SeraCare
MedGenome Labs Private Ltd
Myriad Genetics Inc
Princeton CryoTech
QIAGEN
Quest Diagnostics Inc
STEMCELL Technologies Inc
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Genetic Testing
-Next generation sequencing
-Real-time PCR
-Fluorescent In-Situ Hybridization
-Fragment Analysis
Conventional Testing
By Application
Prostate
Breast
Colorectal
Endometrial
Lung
Melanoma
Brain
Thyroid
Liver
Ovarian
Others
By End-User
Pharmaceutical and Biotechnology Companies
Hospitals
Contract Research Organizations
Academic Research Institutions